NPPA directs pharma firms to provide PTR, MAT details for 29 formulations

Published On 2021-07-12 08:36 GMT   |   Update On 2022-03-24 05:51 GMT
Advertisement

New Delhi: In order to take appropriate action for ceiling price fixation under the provisions of the DPCO, 2013, the National Pharmaceutical Pricing Authority (NPPA) has asked concerned manufacturers and marketing companies of 29 formulations to furnish information regarding Price To Retailer (PTR) and Moving Annual Turnover (MAT) in value term for the month of March 2021.

In this regard, the Authority has issued an Office Memorandum (OM) requesting the concerned manufacturers / marketing firms provide information on Price To Retailer (PTR) and Moving Annual Turnover (MAT) for the formulations listed in Annexure-A, in the manner specified in Annexure-B.

Annexure-A

SI. No.

Formulation

Dosage form and Strength

1

Abacavir

Tablet60 mg

2

Acetylsalicylic acid

Effervescent/ Dispersible/ Enteric coated Tablet 300 mgto 500 mg

3

Acetylsalicylic acid

Tablet 300 mg to 500 mg (351mg to 500mg)

4

Activated charcoal

Powder (as licensed)

5

Calcium carbonate

Tablet 250 mg

6

Calcium folinate

Injection 3 mg/ml

7

Cloxacillin

Oral Liquid 125 mg/5 ml

8

Cycloserine

Capsule 125 mg

9

Dapsone

Tablet 50 mg

10

Doxycycline

Dry syrup 50 mg/5 ml

11

Ethionamide

Tablet 125 mg

12

Ferrous salt (A)+ Folic acid (BJ

Oral liqiud 20 mg elemental iron (A)+ 100 mcg

13

Ferrous salts

Tablet equivalent to 60 mg of elemental iron

14

Hydroxocobalamin

Injection 1 mg/ml

15

lohexol

Injection 140 to 350 mg iodine/ml

16

Lamivudine (A) + Zidovudine

(BJ

Tablet 30 mg (A) + 60 mg (BJ

17

Medroxyprogesteroneacetate

Tablet 5 mg

18

Methylthioninium chloride (Methylene blue)

Injection 10 mg/ml

19

Miltefosine

Capsule 50 mg

20

Nevirapine

Dispersible Tablet 50 mg

21

Nystatin

Pessary 100,000 IU

22

Nystatin

Oral Liquid 100, 000 IU/ml

23

Paromomycin

Injection 375 mg/ml

24

Povidone iodine

Drops 5%

25

Pyridoxine

Tablet 50 mg

26

Sodium chloride

Injection 3%

27

Vitamin A

Oral liquid 100000 JU/ml

28

Zidovudine

Oral liquid 50 mg/5 ml

29

Zidovudine (A)+ Lamivudine

(B) + Nevirapine (C)

Tablet 60 mg (A) + 30 mg (B) + 50 mg (C)

Annexure-B

Name of the Company: _______________________________________________________

SI.

No.

Medicine

Dosage form and Strength

Brand

Pack size

Moving Annual

Turnover (MAT) as on March 2021

Price To Retailer(PTR) as on March 2021

To view the official OM, click the link below:

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News